AFG3L2

Across TCGA pan-cancer cohorts, AFG3L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AFG3L2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher AFG3L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AFG3L2 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

COAD, UCEC, and LUAD are the cancer types where AFG3L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.889	.023	48	view →
UCEC	DFS	Median	All	0.841	0.962	.015	10	view →
LUAD	OS	Quartile	II,III,IV	0.364	0.822	.024	6	view →
LSCC	DFS	Quartile	II,III,IV	0.848	0.431	.024	5	view →
CCRCC	DFS	Tertile	All	0.878	0.640	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AFG3L2–COAD (DFS)

Open the COAD breakdown →